Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma: A Meta-Analysis.
Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma: A Meta-Analysis.
复制标题
生存素在弥漫性大 B 细胞淋巴瘤中的预后和临床病理学价值：荟萃分析。
DOI：
10.1097/md.0000000000001432
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Wang Xin
中科院分区：
文献类型：
--
作者：
Zhang Ya;Wang Jianhong;Sui Xiaohui;Li Ying;Lu Kang;Fang Xiaosheng;Jiang Yujie;Wang Xin
迄今为止，生存素作为一种著名的细胞凋亡抑制剂，作为弥漫性大B细胞淋巴瘤（DLBCL）的潜在生物标志物和治疗靶点引起了广泛关注。然而，对于异质性结果仍然没有达成共识。在此，进行荟萃分析以阐明生存素状态对 DLBCL 患者的预后和临床病理学的令人信服的意义。
Up to date, survivin, a well-known inhibitor of apoptosis, has attracted considerable attention as a potential biomarker and therapeutic target in diffuse large B-cell lymphoma (DLBCL). Nevertheless, there still remains no consensus on heterogeneous results. Herein, a meta-analysis was performed to clarify a convincing significance of survivin status on prognosis and clinicopathology of DLBCL patients.